Radium-223 (Ra-223) Re-Treatment (Re-tx) : First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC)
Clinical Advances in Hematology and Oncology H&o 14(4 Suppl. 5): 10-11
2016
ISSN/ISBN: 1543-0790 PMID: 27167843 Document Number: 686350
Document emailed within 1 workday
Related Documents
2016: Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases Clinical Advances in Hematology and Oncology: H&o 14(4 Suppl. 5): 3-7Bourlon, M.T.; Glodé, L.M.; Crawford, E.D. 2014: Base of the skull metastases in metastatic castration-resistant prostate cancer Oncology 28(12): 1115-1116; 1124
Ecstein-Fraisse, E.; Su, Z. 2014: Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(7): 817-822
Lavelli, V.; Nappi, A.G.; Caputo, P.; Asabella, A.N.; Fanelli, M.; Sardaro, A.; Altini, C.; Ferrari, C.; Rubini, G. 2019: Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases Hellenic Journal of Nuclear Medicine 22(Suppl 2): 153-163
Wang, W.; Peng, R.-x.; Shi, G.-w.; Chen, S.-y.; Ding, Q.; He, J.-y. 2015: Treatment of castration-resistant prostate cancer: Evidence-based clinical practice Zhonghua Nan Ke Xue 21(12): 1121-1124
Hakariya, T.; Sakai, H. 2016: Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 74(1): 137-142
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Azuma, K.; Kawakami, K.; Yuasa, T.; Sugisaki, T.; Hashimoto, K.; Aoyama, T.; Suzuki, K.; Yonese, J.; Hama, T. 2018: Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(12): 1737-1742
Jager, P.L.; Mensink, H.J.; van den Bergh, A.C.; Piers, D.A. 1999: A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment Nederlands Tijdschrift Voor Geneeskunde 143(19): 969-973
Naito, S.; Shiota, M. 2014: The concept and mechanisms of castration-resistant prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2090-2094
Vázquez-Alonso, F.; Puche-Sanz, I.; Cózar-Olmo, J.é M. 2018: Recommendations for follow up in castration resistant prostate cancer Archivos Espanoles de Urologia 71(8): 735-742
Rosino, A.; Ballester, I.; Tudela, J.án.; González-Billalabeitia, E. 2018: Chemotherapy in metastatic castration resistant prostate cancer Archivos Espanoles de Urologia 71(8): 676-684
Miyake, H.; Fujisawa, M. 2014: Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2121-2125
Ojeda, A.V.; Ledo, M.ía.J.é; Alvarez-Ossorio, J.é L.ís. 2018: Sequencing and combination of agents in castration resistant prostate cancer Archivos Espanoles de Urologia 71(8): 711-720
Gomella, L.G.; Petrylak, D.P.; Shayegan, B. 2014: Current management of advanced and castration resistant prostate cancer Canadian Journal of Urology 21(2 Supp 1): 1-6
Bishr, M.; Lattouf, J.B.; Gannon, P.O.; Saad, F. 2011: Updates on therapeutic targets and agents in castration-resistant prostate cancer Minerva Urologica e Nefrologica 63(2): 131-143
Maeno, A.; Habuchi, T. 2016: Current status of castration-resistant prostate cancer translational research Nihon Rinsho. Japanese Journal of Clinical Medicine 74(1): 40-44
Saitou, Y.; Hatanaka, Y.; Imanishi, M.; Ohzeki, T.; Hashimoto, K.; Sugimoto, K.; Esa, A.; Kajikawa, H.; Yasuda, M.; Yamamoto, Y.; Uemura, H. 2012: Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel Hinyokika Kiyo. Acta Urologica Japonica 58(1): 7-11
Hu, Y.-H.; Guo, J.-C.; Zhang, M. 2017: Bipolar androgen therapy: a novel therapeutic strategy for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(12): 1138-1140
Bejrananda, T.; Pripatnanont, C.; Tanthanuch, M.; Karnjanawanichkul, W. 2016: Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer Journal of the Medical Association of Thailand 99(12): 1315-1321